Potential anti-inflammatory effects of the hydrophilic fraction of pomegranate (Punica granatum L.) Seed oil on breast cancer cell lines

Molecules

Volumn 19, Issue 6, 2014, Pages 8644-8660

  Costantini, Susan ^a   Rusolo, Fabiola ^a   De Vito, Valentina ^b   Moccia, Stefania ^b   Picariello, Gianluca ^b   Capone, Francesca ^a   Guerriero, Eliana ^a   Castello, Giuseppe ^a   Volpe, Maria Grazia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

Anti inflammatory effects; Bioactive molecules; Cell viability; Cytokines; Pomegranate (Punica granatum L.)

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYTOKINE; LINOLENIC ACID; PLANT EXTRACT; PUNICIC ACID; VEGETABLE OIL;

APOPTOSIS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL PHENOMENA; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HEPG2 CELL LINE; HT 29 CELL LINE; HUMAN; INFLAMMATION; LYTHRACEAE; MCF 7 CELL LINE; METABOLISM; PLANT SEED; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DRUG SYNERGISM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INFLAMMATION; LINOLENIC ACIDS; MCF-7 CELLS; PLANT EXTRACTS; PLANT OILS; PUNICACEAE; SEEDS;

EID: 84903270439     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19068644     Document Type: Article

References (36)

1. Wang Z.; Pan Z.; Ma H.; Atungulu G.G. Extract of phenolics from pomegranate peels. Open Food Sci. J. 2011 5 17-25.
2. Lansky E.P.; Newman R.A. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J. Ethnopharmacol. 2007 109 177-206.
3. Rasheed Z.; Akhtar N.; Anbazhagan N.A.; Ramamurthy S.; Shukla M.; Haqqi T.M. Polyphenol-rich pomegranate fruit extract (POMx) suppresses PMACI induced expression of pro-inflammatory cytokines by inhibiting the activation of MAP Kinases and NF-κB in human KU812 cells. J. Inflam. 2009 6 1.
4. Larrosa M.; Gonzá lez-Sarrías A.; García-Conesa M.T.; Francisco A.T.B.; Espín J.C. Urolithins ellagic acid-derived metabolites produced by human colonic mi croflora exhibit estrogenic and antiestrogenic activities. J. Agric. Food Chem. 2006 54 1611-1620.
5. Elfalleh W.; Tlili N.; Nasri N.; Yahia Y.; Hannachi H.; Chaira N.; Ying M.; Fe rchichi A. Antioxidant capacities of phenolic compounds and tocopherols from tunisian pomegranate (Punica granatum) fruits. J. Food Sci. 2011 76 707-713.
6. Fadavi A.; Barzegar M.; Azizi M.H. Determination of fatty acids and total lipid content in oilseed of 25 pomegranates varieties grown in Iran. J. Food Compos. Anal. 2006 19 676-680.
7. Kasimsetty S.G. Bialonska D. Reddy M.K. Ma G. Khan S.I. Ferreira D Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J. Agric. Food Chem. 2010 58 2180-2187.
8. Albrecht M.; Jiang W.; Kumi-Diaka J.; Lansky E.P.; Gommersall L.M. Pomegranate extracts potently suppress proliferation Xenograft growth and invasion of human prostate cancer cells. J. Med. Food 2004 7 274-283
9. Ad hami V.M.; Khan N.; Mukhtar H. Cancer chemoprevention by pomegranate: Laboratory and clinical evidence. Nutr. Cancer 2009 61 811-815.
10. Afaq F.; Zaid M.A.; Khan N.; Dreher M.; Mukhtar H. Protective effect of pomegranatederived products on UVB-mediated damage in human reconstituted skin. Exp. Dermatol. 2009 18 553-561.
11. Schubert S.Y; Lansky E.P.; Neeman I. Antioxidan t and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J. Ethnopharmacol. 1999 66 11-17.
12. Straccia M.C.; Siano F.; Coppola R; la Cara F.; Volpe M.G. Extraction and characterization of vegetable oils from cherry seed by different extraction processes. Chem. Eng. Trans. 2012 27 391-396.
13. Kohno H.; Suzuki R.; Yasui Y.; Hosokaw a M.; Miyashita K.; Tanaka T. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Sci. 2004 95 481-486.
14. Arzu A.B.; Tulay O.; Lutfiye Y.E. The Therapeutic Potential of Pomegranate and Its Products for Prevention of Cancer Cancer Prevention-From Mechanisms to Translational Benefits; Tech-Open Access Company: Rijeka Croatia 2012; pp. 331-372.
15. Hora J.J.; Maydew E.R.; Lansky E.P.; Dwivedi C. Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J. Med. Food 2003 6 157-161.
16. Far ia A.; Calhau C. The Bioactivity of pomegranate: Impact on health and disease. CRC Crit. Rev. Food Sci. Nutr. 2011 51 626-634.
17. Caligiani A; Bonzanini F.; Palla G.; Cirlini M.; Brun i R. Characterization of a potential nutraceutical ingredient: Pomegranate (Punica granatum L.) seed oil unsaponifiable fraction. Plant. Foods Hum. Nutr. 2010 65 277-283.
18. Adams L.S.; Seeram N.P.; Aggarwal B.B.; Takada Y.; Sand D.; Heber D. Pomegranate juice total pomegranate ellagitannins and punicalagin suppress inflammatory cell signaling in colon cancer Cells. J. Agric. Food Chem. 2006 54 980-985.
19. Malik A.; Afaq F.; Sarfaraz S.; Adhami V.M.; Syed D.N.; Mukhtar H. Pomegranate fruit Juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 2005 2 14813-14818.
20. Pande G.; Akoh C.C. Antioxidant capacity and lipid characterization of six Georgia-grown pomegranate cultivars. J. Agric. Food Chem. 2009 57 9427-9436.
21. Jing P.; Tian Y.; Shi H.; Sheng Y.; Slavin M.; Gao B.; Liud L.; Yu L. Antioxidant properties and phytochemical composition of China-grown pomegranate seeds. Food Chem. 2012 132 1457-1464.
22. Turtygin A.V; Deineka V.I.; Deineka L.A. Determination of the triglyceride composition of pomegranate seed oil by reversed-phase HPLC and spectrophotometry. J. Anal. Chem.2013 68 558-563.
23. Hontecillas R.; O'Shea M.; Einerhand A.; Diguardo M.; Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J. Am. Coll. Nutr. 2009 28 184-195.
24. Bassaganya-Riera J.; DiGuardo M.; Climent M.; Vives C.; Carbo A.; Jouni Z.E.; Einerhand A.W.; O'Shea M.; Hontecillas R. Activation of PPARγ and δ by dietary punicic acid ameliorates intestinal inflammation in mice. Br. J. Nutr. 2011 106 878-886.
25. Dehqanzada Z.A.; Storrer C.E.; Hueman M.T.; Foley R.J.; Harris K.A.; Jama Y. H.; Shriver C.D.; Ponniah S.; Peoples G.E. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol. Rep. 2007 17 687-694.
26. Salc edo R.; Ponce M.L.; Young H.A.; Wasserman K.; Ward J.M.; Kleinman H.K.; Oppenheim J.J.; Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progress ion. Blood 2000 196 34-40.
27. Kolls J.K.; Linden A. Interleukin-17 family members and infiammation. Immunity 2004 21 467-476.
28. Fabregat I Dysregulation of apoptosis in hepatocellular carcinoma cells. World J. Gastroenterol. 2009 15 513-520.
29. Feurino L.W.; Zhang Y.; Bharadwaj U.; Zhang R.; Li F.; Fisher W.E.; Brunicardi F.C .; Chen C.; Yao Q.; Min L. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol. Ther. 2007 6 1096-1100.
30. Ren M.; Guo Q.; Guo L.; Lenz M.; Qian F.; Koenen R.R.; Xu H.; Schilling A.B.; Weber C.; Ye R.D.; et al. WJPolymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. 2010 129 3952-3966.
31. Waldmann T.A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006 6 595-601.
32. Dun X.; Li X.Q.; Li L.; Xu Y.Y.; Feng Y.M. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: A better approach for subtyping breast cancer and predicting prognosis. Breast Cancer Res. Treat. 2013 138 59-67.
33. Glynn S.A.; Boersma B.J.; Dorsey T.H.; Yi M.; Yfantis H.G.; Ridnour L.A.; Martin D.N.; Switzer C.H.;. Hudson R.S.; Wink D.A.; et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J. Clin. Invest. 2010 120 3843-3854.
34. Singleton V.L.; Rossi J.A. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am. J. Enol. Viticult. 1965 16 144-158.
35. Brand-Williams W.; Cuvelier M.E.; Berset C. Use of free radical method to evaluate antioxidant activity. LWT-Food Sci. Technol. 1995 28 25-30.
36. Rusolo F.; Pucci B.; Colonna G.; Capone F.; Guerriero E.; Milone M.R.; Nazzaro M.; Volpe M.G.; di Bernardo G.; Castello G.; et al. Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines. Molecules 2013 18 2549-2562.